The treatment of uveitic cystoid macular edema with topical Interferon gamma
The treatment of uveitic cystoid macular edema with topical Interferon gamma
批准号:
10266892
负责人:
Sheldon Miller
金额:
$2.92万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
3-DimensionalAgeAngiogenic FactorAnteriorBathingBiological AssayBlood capillariesCell SurvivalCellsCorneaCystoid Macular EdemaDiseaseDropsEdemaEndothelial CellsEquilibriumEyeEyedropsFluoresceinHourHumanHydration statusImageImmune systemIn VitroInflammasomeInflammationInflammatoryInterferon Type IIInterferonsInterleukin-18Interleukin-6LeadLiquid substanceMeasuresMicroRNAsNeural RetinaOptical Coherence TomographyPathogenesisPathologicPathway interactionsPatientsPhosphate BufferPhysiologic Intraocular PressurePlayResistanceRetinaRetinal DetachmentRodent ModelRoleSalineSecondary toSeriesSideSignal Transduction PathwayStainsStructure of retinal pigment epitheliumSurfaceTestingTherapeutic EffectThickTimeTissuesToxic effectUveitisVisual Acuityabsorptionangiogenesisbody systemcell growthconjunctivacytokineexperimental studyhuman fetal retinal pigment epithelial cellin vivo evaluationirritationmaculamonolayerocular surfaceprimary outcomereceptorresponsesecondary outcome
中文摘要
点击翻译按钮获取中文摘要
英文摘要
We hypothesize that proper retinal hydration is maintained by a balance of the bimodal functions of interferon gamma on the retinal pigment epithelium. Mounting evidence strongly suggests that the immune system plays an important role in angiogenesis. Pro-inflammatory cytokines, such as IFNg, IL-6, TNFa and IL-1b are the major cytokines in the pathogenesis of ocular inflammatory diseases and been shown to have receptors on RPE. TNFa, IL-6 and IL-1b are regarded as pro-angiogenic factors. However, IFNg is widely accepted as an anti-angiogenic cytokine due to its inhibitory effect on endothelial cell growth and capillary formation in other organ systems. We have evaluated the effect of interferon gamma on the JAK/STAT pathway, a signal transduction pathway also present in Human RPE cells. Fluid transport assays were performed to examine whether IFN induced changes in fluid transport across hfRPE monolayers. IFNg (10 ng/ml) addition to the basal bath increased JV by 8.6 ulcm-2hr-1, reflecting an increase in fluid absorption from the retinal to the choroidal side of the tissue. There were no apparent changes in cell viability as measured by transepithelial potential (TEP) and total tissue resistance (RT). In 10 experiments, the mean JV increased from 12.9 +/- 1.6 to 20.5 +/- 3.1 uL*cm-2*hr-1 (mean +/- s.e.m., P< 0.01). A previously tested in vivo rodent model of retinal detachment was used to measure the effect of INFg on re-absorption following retinal detachment. Initial detachment was created by injecting approximately 1ul of osmotically-balanced, modified phosphate-buffered saline (MPBS) solution into the sub-retinal space (SRS). Detachments that did not change in volume more than 10% in the first 30 minutes were used to test INFg effects. After detachment stabilization volume was measured by OCT imaging, INFg (40ul of 100ng/ml) was added to the anterior surface of the eye via eye drops (Celluvisc). A series of 3D OCT images were recorded at different time point. Addition of INFg to the anterior eye surface caused a significant, rapid 50% decrease in retinal detachment volume in the first hour of observation. This result is consistent with the observed fluid transport increase in RPE cells in vitro. We hypothesize that in the normal RPE cell, both pathways are functioning simultaneously to maintain the normal retinal hydration. The Jak/Stat pathway, if stimulated from basal side, will induce fluid absorption to resolve the abnormal accumulation of edema. Other regulatory targets of Jak/Stat pathway include micro RNA 155(miR-155), inflammasome, and IL-18 secretion. We also hypothesize that monotonic elevation of steady-state miR-155 levels in RPE occur with age, contributing to constitutive inflammasome activation. Modulation of IL-18 and IFNg levels may lead to therapeutic effect to reverse pathological changes associated with uveitis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The treatment of uveitic cystoid macular edema with topical Interferon gamma
-
批准号:7968430
-
项目类别:
-
资助金额:$3.06万
-
财政年份:--
-
负责人:Sheldon Miller
-
依托单位:
Human Retinal Pigment Epithelial Cell Cultures: Physiology & Fluid Transport
-
批准号:7968352
-
项目类别:
-
资助金额:$44.41万
-
财政年份:--
-
负责人:Sheldon Miller
-
依托单位:
Biological function microRNAs enriched in RPE: in vitro and in vivo models
-
批准号:7968404
-
项目类别:
-
资助金额:$25.72万
-
财政年份:--
-
负责人:Sheldon Miller
-
依托单位:
Protective effects of neurotrophic factors on RPE physiology
-
批准号:7968410
-
项目类别:
-
资助金额:$9.19万
-
财政年份:--
-
负责人:Sheldon Miller
-
依托单位:
AG13764 and AG13711 Reverses VEGF-Induced Choroidal Neovascularization in Rat Eye
-
批准号:7968355
-
项目类别:
-
资助金额:$4.59万
-
财政年份:--
-
负责人:Sheldon Miller
-
依托单位:
Animal models of eye diseases
-
批准号:8339786
-
项目类别:
-
资助金额:$72.11万
-
财政年份:--
-
负责人:Sheldon Miller
-
依托单位:
Human Retinal Pigment Epithelial Physiology
-
批准号:8339776
-
项目类别:
-
资助金额:$103.25万
-
财政年份:--
-
负责人:Sheldon Miller
-
依托单位:
Lactate transport and pH-regulation in the human RPE
-
批准号:7734651
-
项目类别:
-
资助金额:$28.34万
-
财政年份:--
-
负责人:Sheldon Miller
-
依托单位:
NEI New Space Activation & Commissioning
-
批准号:7970430
-
项目类别:
-
资助金额:$10.61万
-
财政年份:--
-
负责人:Sheldon Miller
-
依托单位:
pH-dependent ion- transport mechanism in the hfRPE
-
批准号:8149180
-
项目类别:
-
资助金额:$26.53万
-
财政年份:--
-
负责人:Sheldon Miller
-
依托单位:
Central serous chorioretinopathy mouse model
-
批准号:8149202
-
项目类别:
-
资助金额:$3.12万
-
财政年份:--
-
负责人:Sheldon Miller
-
依托单位:
Effect of oxidative stress on RPE and its pertinence to the pathogenesis of AMD
-
批准号:7968402
-
项目类别:
-
资助金额:$7.66万
-
财政年份:--
-
负责人:Sheldon Miller
-
依托单位:
Animal models of eye diseases
-
批准号:8556842
-
项目类别:
-
资助金额:$68.91万
-
财政年份:--
-
负责人:Sheldon Miller
-
依托单位:
The treatment of uveitic cystoid macular edema with topical Interferon gamma
-
批准号:8938335
-
项目类别:
-
资助金额:$14.06万
-
财政年份:--
-
负责人:Sheldon Miller
-
依托单位:
pH-dependent ion- transport mechanism in the hfRPE
-
批准号:7594102
-
项目类别:
-
资助金额:$17.31万
-
财政年份:--
-
负责人:Sheldon Miller
-
依托单位:
Biological function microRNAs enriched in RPE: in vitro and in vivo models
-
批准号:7734654
-
项目类别:
-
资助金额:$19.48万
-
财政年份:--
-
负责人:Sheldon Miller
-
依托单位:
JAM-C in retinal pigment epithelium
-
批准号:7734645
-
项目类别:
-
资助金额:$46.05万
-
财政年份:--
-
负责人:Sheldon Miller
-
依托单位:
Effect of oxidative stress on RPE and its pertinence to the pathogenesis of AMD
-
批准号:7734653
-
项目类别:
-
资助金额:$8.86万
-
财政年份:--
-
负责人:Sheldon Miller
-
依托单位:
Biological function microRNAs enriched in RPE: in vitro and in vivo models
-
批准号:8149189
-
项目类别:
-
资助金额:$30.9万
-
财政年份:--
-
负责人:Sheldon Miller
-
依托单位:
Angiogenic and Anti-Angiogenic Factors in human RPE
-
批准号:8149172
-
项目类别:
-
资助金额:$21.85万
-
财政年份:--
-
负责人:Sheldon Miller
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: